Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 075 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 075 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid composition, nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration, with dextrose being metabolized to carbon dioxide and water, supplying energy.
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Intravenous administration at a rate not exceeding 10 mEq/hour of potassium chloride; typical adult dose is 20-40 mEq per day administered as an additive to dextrose 5% solution, titrated to serum potassium levels.
Intravenous; typical adult dose is 10-20 mEq/hour, not exceeding 40 mEq/hour or 150 mEq/day, with continuous cardiac monitoring and serum potassium monitoring.
None Documented
None Documented
Potassium has a biphasic elimination: distribution half-life ~1 hour, terminal elimination half-life ~12 hours in normal renal function. Clinical context: Half-life extends significantly in renal impairment, requiring dose adjustment.
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
Potassium is primarily excreted renally (approximately 90%) via glomerular filtration and distal tubular secretion. Minor fecal elimination accounts for ~10%. Renal excretion is influenced by aldosterone, acid-base status, and potassium intake.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 mEq per 100 mL (approximately 20 mEq/L).
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement